Point of Care Diagnostics Global Market Analysis 2024

$4,500.00$7,000.00

The Global Point of Care Diagnostics Market is projected to reach $80.67 billion by 2028, from a value of $37.93 billion in 2022, by registering a CAGR of 13.4% during the forecast period 2022 – 2028

Clear
SKU: ER1098 Category:
© Epson Research 2021
Share this infographic on
Published Year:
2024
Region:
Global
Forecast period:
2021-2027
Report Coverage:

Market Trends and analysis of the crucial market segments across North America, Europe, Asia Pacific and Rest of the World.

Report Format:
PDF

5 User License

$ 5,500

  • Access to Five users
  • Print upto 5 copies
  • PDF & Excel Formats

Corporate User License

$ 7,000

  • Unlimited users within company
  • Free Yearly update
  • PDF & Excel Formats

The Global Point of Care Diagnostics Market is projected to reach $80.67 billion by 2028, from a value of $37.93 billion in 2022, by registering a CAGR of 13.4% during the forecast period. The prevalence of chronic diseases, high prevalence of the diabetic population, the need for early detection of hypo and hyperglycemic diabetes, greater awareness, and availability of glucose monitors across the globe, and, rising adoption of decentralized healthcare systems, are the major factors propelling the growth of the market. However, the adoption of point-of-care test kits (POCT) and, stringent regulatory policies are hampering the market growth. Moreover, increasing provider awareness about novel technologies, growing investments, and funding for product development are creating ample opportunities across the globe.

Recent Developments

In January 2022, Roche launched its Cobas Pulse System in select countries accepting the CE Mark. This is Roche Diagnostics’ newest generation of connected point-of-care solutions for professional blood glucose management.

In December 2021, Pfizer In and Arena Pharmaceuticals, Inc have announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.

In October 2021, Thermo Fisher Scientific announced that it received Emergency Use Authorization (EUA) from the FDA to run COVID-19 tests from new saliva sample collection method with the Spectrum Solutions SpectrumDNA SDNA-1000 collection device, a high-throughput, automated COVID-19 testing system on the Amplitude Solution..

In, July 2021, Abbott announced the launch of the Panbio COVID-19 Antigen Self-Test,which can be used to detect the SARS-CoV-2 virus in adults and children. The test received CE Mark approval and is also approved by the ICMR advisory in India.

Competitive Landscape

Trinity Biotech, Siemens, Sekisui Diagnostics, Roche Diagnostics (A Subsidiary of F. Hoffmann-La Roche Ltd.), Quidel, PTS Diagnostics (A Part of Sinocare Inc.), Nova Biomedical, Johnson & Johnson, Instrumentation Laboratory (A Werfen Company), EKF Diagnostics, Danaher Corporation, Chembio Diagnostics, Becton, Dickinson, and Company (BD), Accubiotech, Abbott Laboratories are some of the major players in the Global Point of Care Diagnostics Market.

TABLE OF CONTENTS

1 Summary
2 Market Overview
2.1 Abstract
2.2 Research Sources
2.3 Research Findings
2.4 Assumptions
3 Market Dynamics
3.1 Drivers & Opportunities
3.2 Restraints & Threats
3.3 Regulatory Affairs
3.4 Supplychain Analysis
3.5 PORTERS Analysis
4 Competitive Landscape
5 Point of Care Diagnostics Market by Prescription Mode
5.1 Prescription-Based Testing
5.2 Over the Counter Testing
6 Point of Care Diagnostics Market by Platform
6.1 Lateral Flow Assays (Immunochromatography Tests)
6.2 Agglutination Assays
6.3 Biosensors
6.4 Dipsticks
6.5 Immunoassays
6.6 Microfluidics
6.7 Molecular Diagnostics
6.8 Solid Phase
7 Point of Care Diagnostics Market by Product
7.1 Tumor/Cancer Marker Testing
7.2 Pregnancy and Fertility Testing
7.3 Urinalysis Testing
7.4 Cholesterol Testing
7.5 Glucose Monitoring
7.5.1 Lancets & Lancing Devices
7.5.2 Meters
7.5.3 Strips
7.6 Hematology and Hemostasis Testing
7.7 Fecal Occult Testing
7.8 Drug and Alcohol Abuse Testing
7.9 Infectious Disease Testing Products
7.9.1 Tropical Disease Testing
7.9.2 Sexually Transmitted Disease (STD) Testing
7.9.3 Respiratory Infection Testing
7.9.4 Influenza Testing
7.9.5 Human Immunodeficiency Virus (HIV) Testing
7.9.6 Hepatitis C Testing
7.9.7 Healthcare-Associated Infection (HAI) Testing
7.10 Cardiometabolic Testing
7.10.1 Blood Gas/Electrolytes Testing
7.10.2 Cardiac Marker Testing
7.10.3 HBA1C Testing
7.11 Coagulation Monitoring Products
7.11.1 Prothrombin Time (PT)/International Normalized Ratio (INR) Testing
7.11.2 Activated Clotting Time (ACT/APTT) Testing
8 Point of Care Diagnostics Market by Application
8.1 Interventional Clinical Trials
8.2 Observational Clinical Trials
9 Point of Care Diagnostics Market by End User
9.1 Professional Diagnostic Centers
9.1.1 Hospitals/Critical Care Centers
9.1.2 Outpatient Healthcare & Ambulatory Care Settings
9.2 Research Laboratories
9.3 Home Care
9.4 Assisted Living Healthcare Facilities
9.5 Other End Users
9.5.1 Not-for-Profit Organizations
9.5.2 Medical Universities
10 Point Of Care Diagnostics Market by Regions
10.1 North America
10.2 Europe
10.3 Asia Pacific
10.4 Rest of the World
11 Company Profiles
11.1 Trinity Biotech
11.2 Siemens
11.3 Sekisui Diagnostics
11.4 Roche Diagnostics (A Subsidiary of F. Hoffmann-La Roche Ltd.)
11.5 Quidel
11.6 PTS Diagnostics (A Part of Sinocare Inc.)
11.7 Nova Biomedical
11.8 Johnson & Johnson
11.9 Instrumentation Laboratory (A Werfen Company)
11.10 EKF Diagnostics
11.11 Danaher Corporation
11.12 Chembio Diagnostics
11.13 Becton, Dickinson, and Company (BD)
11.14 Accubiotech
11.15 Abbott Laboratories